Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

February 29, 2012

Conditions
Rectal Neoplasms
Interventions
RADIATION

Radiotherapy

Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement \> 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.

DRUG

Tom-OX

The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.

All Listed Sponsors
lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

NCT02723253 - Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter